KEY FEATURES
| Full Name | Cytochrome P450 7A1 |
|---|---|
| Synonym | CYP7; CYP7-A1; CYPVII; Cholesterol 7 Alpha Hydroxylase; Cytochrome P450 Family 7 Subfamily A Polypeptide 1 |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 0.78-50ng/mL |
| Sensitivity | 0.29ng/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human CYP7A1 in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human CYP7A1. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human CYP7A1 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human CYP7A1, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human CYP7A1. You can calculate the concentration of Human CYP7A1 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES
TYPICAL DATA
Human CYP7A1 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (ng/mL) | 2.65 | 7.62 | 24.83 | 2.48 | 7.57 | 26.47 |
| Standard deviation | 0.14 | 0.42 | 1.3 | 0.15 | 0.36 | 1.26 |
| CV(%) | 5.42 | 5.52 | 5.25 | 6.11 | 4.72 | 4.77 |
RECOVERY
The recovery of Human CYP7A1 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 95-109 | 102 |
| EDTA plasma (n=8) | 86-100 | 91 |
| Cell culture media (n=8) | 90-103 | 97 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human CYP7A1 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.
Products associated with CYP7A1 ELISA Kits
| CYP27A1 ELISA Kit | publications with CYP7A1 and CYP27A1 |
| NR5A2 ELISA Kit | publications with CYP7A1 and NR5A2 |
| NR0B2 ELISA Kit | publications with CYP7A1 and NR0B2 |
| NR1H4 ELISA Kit | publications with CYP7A1 and NR1H4 |
| PPARA ELISA Kit | publications with CYP7A1 and PPARA |
| POR ELISA Kit | publications with CYP7A1 and POR |
| HSD3B2 ELISA Kit | publications with CYP7A1 and HSD3B2 |
| HSD3B7 ELISA Kit | publications with CYP7A1 and HSD3B7 |
Pathways associated with CYP7A1 ELISA Kit
| Bile Acid And Bile Salt Metabolism Pathway | Bile Acid And Bile Salt Metabolism Pathway |
| Bile Acid Biosynthesis, Cholesterol => Cholate/chenodeoxycholate Pathway | Bile Acid Biosynthesis, Cholesterol => Cholate/chenodeoxycholate Pathway |
| Bile Secretion Pathway | Bile Secretion Pathway |
| Biological Oxidations Pathway | Biological Oxidations Pathway |
| Cytochrome P450 - Arranged By Substrate Type Pathway | Cytochrome P450 - Arranged By Substrate Type Pathway |
| Drug Induction Of Bile Acid Pathway | Drug Induction Of Bile Acid Pathway |
| Endogenous Sterols Pathway | Endogenous Sterols Pathway |
| Fatty Acid, Triacylglycerol, And Ketone Body Metabolism Pathway | Fatty Acid, Triacylglycerol, And Ketone Body Metabolism Pathway |
Diseases associated with CYP7A1 ELISA Kit
| Hypercholesterolemia | publications with CYP7A1 and Hypercholesterolemia |
| Fatty Liver | publications with CYP7A1 and Fatty Liver |
| Dyslipidemias | publications with CYP7A1 and Dyslipidemias |
| Hyperlipidemias | publications with CYP7A1 and Hyperlipidemias |
| Liver Diseases | publications with CYP7A1 and Liver Diseases |
| Atherosclerosis | publications with CYP7A1 and Atherosclerosis |
| Cardiovascular Diseases | publications with CYP7A1 and Cardiovascular Diseases |
| Cholestasis | publications with CYP7A1 and Cholestasis |
| Liver Neoplasms | publications with CYP7A1 and Liver Neoplasms |
| Inflammation | publications with CYP7A1 and Inflammation |
Organs/Tissues associated with CYP7A1 ELISA Kit
| Liver | publications with CYP7A1 and Liver |
| Embryonic Tissue | publications with CYP7A1 and Embryonic Tissue |
| Intestine | publications with CYP7A1 and Intestine |
| Pancreas | publications with CYP7A1 and Pancreas |
| Testis | publications with CYP7A1 and Testis |
| Brain | publications with CYP7A1 and Brain |
| Adrenal Gland | publications with CYP7A1 and Adrenal Gland |
| Kidney | publications with CYP7A1 and Kidney |
| Lung | publications with CYP7A1 and Lung |
| Muscle | publications with CYP7A1 and Muscle |
